Starting A New Conversation In Mental Health

By David Hewitt, Chief Medical Officer, INC Research/inVentiv Health

To improve care, we need more wide-ranging discussions among patients, payers, physicians and pharmaceutical companies

When we talk about access to healthcare in the U.S., questions often arise about who should shoulder the high costs of hard-to-develop medicines for cancer or orphan diseases. The spotlight rarely lands on drugs for psychiatric illnesses—and the reason is simple. We currently have an abundance of relatively inexpensive generic treatments for illnesses such as depression and anxiety.